About
No specific interactions with imaging contrast agents are known, but testosterone therapy can influence certain lab tests (such as PSA, hematocrit, and lipid levels), so clinicians interpreting results should know a patient is using it. Early signs and symptoms of puberty have occurred in young childrenwho have come in direct contact with testosterone by touching areas where menhave used Vogelxo. Children and women should avoid contact with theunwashed or not covered (unclothed areas) where Vogelxo has been applied toyour skin. Vogelxo can transfer from your body to othersincluding, children and women. The study demonstrated that the overall effect of washing wasto decrease testosterone concentrations; however, when washing occurred two ormore hours post drug application, serum testosterone concentrations remainedwithin the normal range. In a clinical study conducted to evaluate the effect ofhand washing on the residual amount of testosterone, 36 healthy male subjectsreceived 50 mg of testosterone from 5 g of Vogelxo on a hand and appliedtestosterone gel to the upper arm and shoulder of one side. The potential for dermal testosterone transfer following Vogelxo use was evaluated in a clinical study betweenmales dosed with Vogelxo and their untreated female partners.The average daily DHTconcentration produced by testosterone gel 100 mg at Day 30 was 555 (± 293)pg/mL and by testosterone gel 50 mg at Day 30 was 346 (± 212) pg/mL. The average daily testosteroneconcentration produced by testosterone gel 100 mg at Day 30 was 612 (± 286)ng/dL and by testosterone gel 50 mg at Day 30 was 365 (± 187) ng/dL. In a single dose, replicate crossover study, when Vogelxo100 mg was applied, absorption of testosterone into the blood continued for theentire 24 hour dosing period. Alcohol-based products, including Vogelxo, are flammable;therefore, patients should be advised to avoid fire, flame or smoking until theVogelxo has dried.
In addition, local levels of DHT in so-called androgenic (5α-reductase-expressing) tissues are also markedly reduced, and this can have a strong impact on certain effects of testosterone. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy. Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism. Other side effects include increased hematocrit, which can require venipuncture in order to treat, and exacerbation of sleep apnea. Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5α-reductase inhibitors. Breast cancer is said by some sources to be an absolute contraindication of testosterone therapy, but androgens including testosterone have also actually been used to treat breast cancer.
Major brand names of testosterone and/or its esters include Andriol, Androderm, AndroGel, Axiron, Delatestryl, Depo-Testosterone, Intrinsa, Nebido, Omnadren, Primoteston, Sustanon, Testim, TestoGel, TestoPatch, Testoviron, and Tostran. Additionally, advertising from drug companies selling testosterone and human growth hormone, as well as dietary supplement companies selling all kinds of "boosters" for aging men, have emphasized the "need" of middle-aged or ageing men for testosterone. They largely superseded testosterone propionate and became the major testosterone esters used medically for over half a century. Shortly thereafter, in 1937, testosterone first became commercially available as a pharmaceutical drug in the form of pellets and then in ester form for intramuscular injection as the relatively short-acting testosterone propionate. Prominent examples include nandrolone (19-nortestosterone), metandienone (17α-methyl-δ1-testosterone), and stanozolol (a 17α-alkylated derivative of DHT). Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic. In addition to ester and ether prodrugs, androgen prohormones or precursors of testosterone, such as dehydroepiandrosterone (DHEA), androstenediol, and androstenedione, exist as well, and convert into testosterone to variable extents upon oral ingestion.
There are no testosterone products approved for use in women in the United States and many other countries. It appears that in women, rather than testosterone, estradiol may be the most important hormone involved in sexual desire, although data on the clinical use of estradiol to increase sexual desire in women is limited. In accordance, men experience sexual dysfunction at testosterone levels of below 300 ng/dL, and men that have levels of testosterone of approximately 200 ng/dL frequently experience such problems. The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar. A 2020 guideline from the American College of Physicians supports the discussion of testosterone in adult men with age-related low levels of testosterone who have sexual dysfunction. The primary use of testosterone is the treatment of males with too little or no natural testosterone production, also termed male hypogonadism or hypoandrogenism (androgen deficiency).